May CPI and Housing...
Health Care: Drugs
Omeros Corporation (OMER: NASDAQ)
$5.18 0.21 | 4.23%
06/18/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with OMER
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
Latest OMER Headlines from TheStreet
- Commit To Buy Omeros Corp At $4, Earn 24.7% Annualized 06.03.13 | 01:06 pm
- Short Interest Jumps 41.2% For OMER 05.10.13 | 03:05 pm
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: FB LNKD SMM OMER 01.07.13 | 08:01 am
- Omeros Stock Gaps Down On Today's Open (OMER) 06.27.12 | 09:06 am
- 7 Stocks Soaring on Unusual Volume 06.08.12 | 04:06 pm
- 10 Stocks to Watch: Krispy Kreme, Omeros 04.01.11 | 01:04 pm
- Omeros Stock Gaps Down On Today's Open (OMER) 04.01.11 | 09:04 am
- Omeros, EXFO: After-Hours Trading 03.31.11 | 05:03 pm
- IPO Comeback In 2009 Sets Stage For Busy 2010 12.31.09 | 10:12 am
Press Releases for OMER
- Omeros To Present Additional OMS302 Clinical Data At The Annual ASCRS And ASOA Symposium And Congress - PR Newswire 04.19.13 | 07:04 am
- Omeros Files Orphan Drug Application For Treatment Of Atypical Hemolytic Uremic Syndrome With OMS721 - PR Newswire 04.17.13 | 07:04 am
- Omeros Announces That GPR17 Antagonists Improve Function In Model Of Multiple Sclerosis - PR Newswire 04.10.13 | 07:04 am
- Omeros Announces Positive OMS721 Data In Model Of Thrombotic Microangiopathy - PR Newswire 04.02.13 | 07:04 am
- Omeros To Present At The 2013 Future Leaders In The Biotech Industry Conference - PR Newswire 03.29.13 | 07:03 am
- Omeros Announces Toxicology Data That Support Advancing MASP-2 Inhibitor Into Clinical Trials - PR Newswire 03.28.13 | 07:03 am
- Omeros Announces Successful Completion Of PDE10 Phase 1 Multiple Ascending Dose Trial - PR Newswire 03.26.13 | 07:03 am
- Omeros Elucidates Mechanism Of Its PDE7 Inhibitors In Addiction - PR Newswire 03.19.13 | 07:03 am
- Omeros To Present At The Cowen And Company 33rd Annual Health Care Conference - PR Newswire 03.01.13 | 07:03 am
- Omeros Announces Toxicology Study Data From MASP-2 Inhibitor - PR Newswire 02.07.13 | 07:02 am
Partner Headlines for OMER
- Omeros Files CTA for aHUS Candidate - Analyst Blog - Zacks 05.30.13 | 12:05 am
- FDA Accepts Omeros' IND for OMS824 - Analyst Blog - Zacks 05.29.13 | 01:05 am
- Is This Biotech A Value Stock Or Value Trap? - Seeking Alpha 03.30.13 | 06:03 am
- Do You Have The Guts To Take On Cutting-Edge Biotech Like This VC? - Seeking Alpha 12.14.12 | 09:12 am
- From Earlier: Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program - Benzinga 10.02.12 | 09:10 am
- Netflix REITERATED Below Average and 3 Analyst-Reiterated Ratings Starting the Week - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- Market Wrap: Markets RALLY, Arena Makes HISTORY, Apple BEATS Samsung - Wall St. Cheat Sheet 06.28.12 | 09:06 am
- Ultimate Market Recap: News Corp. Makes Split Decision, RIM Looking Rough - Wall St. Cheat Sheet 06.28.12 | 08:06 am
- Omeros Eyeing Deals As Ophthalmology Drug Succeeds - Seeking Alpha 03.15.12 | 09:03 am
- UPDATE: Canaccord Upgrades Omeros; Raises PT - Benzinga 03.14.12 | 09:03 am
